12 articles for MO Taha
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3K¿) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
The University of Jordan
Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.
University of Jordan
Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening.
University of Jordan
Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads.
University of Jordan
Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads.
Applied Science University
Discovery of new nanomolar peroxisome proliferator-activated receptor κ activators via elaborate ligand-based modeling.
Universiti Sains Malaysia
Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay.
University of Jordan
Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads.
Applied Science University
Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.
Al-Zaytoonah Private University of Jordan
Homology modeling of MCH1 receptor and validation by docking/scoring and protein-aligned CoMFA.
University of Jordan
Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.
University of Jordan
Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
Achillion Pharmaceuticals